Navigation Links
Molecular Biomarkers for Cancer Detection and Management
Date:11/7/2013

London (PRWEB) November 07, 2013

New to Insight Pharma Reports is Molecular Biomarkers for Cancer Detection and Management: Technologies, Markets, and Trends. This report focuses on recent progress and new directions in this highly dynamic diagnostic field. Covering extensive background and history, commercialization, and marketing trends of cancer biomarker technologies, this report provides heavy detail of historical and evolutionary aspects of cancer biomarkers, delineating some of the difficulties researchers face in validating and commercializing their candidate assays.

Significant highlights of the report include:

•Basic research conducted in both academic and commercial settings divided into three segments: disease detection, prognosis, and companion diagnostics.
-42 detailed descriptions of copmanies (including GenomeDx Biosciences, Genomic Health, Life Technologies, Foundation Medicine, Roche Molecular Systems, and many more!).
•Commercial activity in the three foregoing sectors, and the perspective of market dynamics.
•Focuses on trends and conclusions.
•Data depicted across 15 tables and figures.

Following company descriptions and commercial applications are transcribed interviews of five individuals who are highly knowledgeable in the field, including:

•Genome Diagnostics
•Billings Clinic
•Scientia Advisors
•Cynvenio Biosystems
•Johns Hopkins University School of Medicine

Also provided in the report are survey results of 107 individuals who actively work in the cancer biomarker space. Results are depicted across 9 tables.

Table of Contents

Executive Summary
•Background and history
•Basic research
•Commercial applications
•Market dynamics
•Survey results
•Trends and conclusions

CHAPTER 1: Introduction
•Scope and contents

CHAPTER 2: Background and History
•First-generation cancer biomarkers
•Categorization of cancer biomarkers
•Disease detection biomarkers
•Prognostic biomarkers
•Companion diagnostic biomarkers
•Omic era cancer biomarkers
•Failed efforts and stumbling blocks

CHAPTER 3: Basic Research
•Screening, detection, risk, and monitoring
•Screening
•Prognosis and prediction
•Companion Diagnostics
•Metastasis
•Circulating tumor cells
•Exosomes
•MicroRNA (miRNA)

CHAPTER 4: Commercial Applications
•Screening, detection, risk assessment, and monitoring biomarkers
•Alere
•Allegro Diagnostics
•Atossa Genetics
•Biophysical Corporation
•Exact Sciences
•Exosome Diagnostics
•Matrix-Bio
•MDx Health
•Mitomics
•Myriad Genetics
•Oncimmune
•Onconome
•Predictive Biosciences
•Sphingotec
•Prognosis and prediction biomarkers
•Agendia
•Abbott Molecular
•Atossa Genetics
•Biocept
•bioTheranostics
•DiagnoCure
•GenomeDx Biosciences
•Genomic Health
•Gen-Probe
•Life Technologies
•MetaStat
•Predictive Biosciences
•Skyline Diagnostics
•Trovagene
•Veridex
•Companion diagnostic biomarkers
•20/20 GeneSystems
•Abbott Molecular
•Cynvenio
•Dako (Agilent)
•Epic Sciences
•Foundation Medicine
•Genomic Health
•Molecular Response Corp.
•Nodality
•Personal Genome Diagnostics
•Interview with founder, Luis Diaz, MD
•Qiagen
•Roche Molecular Systems

CHAPTER 5: Market Dynamics
•Competitive Environment
•Sales Estimates and Projections
•Mergers and acquisitions
•Cancer detection, risk, and prognostic assay deals
•Liquid Biopsy AB and Roche
•Oxford Gene Technology
•Abbott and Stanford University
•Ipsogen and Personal Genome Diagnostics (PDGx)
•Companion diagnostic assay deals
•Abbott and Merck
•Affymetrix and Massachusetts General Hospital (MGH)
•Agilent/Dako and Genentech
•Eli Lilly
•Foundation Medicine
•GE Healthcare and Insight Genetics
•Genomic Health and OncoMed Pharmaceuticals
•HTG Molecular Diagnostics and Merck
•Life Technologies and Others
•Qiagen and Boehringer Ingelheim
•Quintiles and Oxford Cancer Biomarkers
•Roche/Ventana and other companies
•Verastem and Labcorp
•Survey Results

CHAPTER 6: Observations and Conclusions
•Companion diagnostics
•Circulating tumor cells and nucleic acids
•EMT biomarkers
•Tumor Heterogeneity
•Costs and reimbursement

CHAPTER 7: Interview Transcripts
•Luis Diaz, MD, Associate Professor of Oncology, Johns Hopkins School of Medicine; Chief Medical Officer and Founder Personal Genome Diagnostics
•Jorge Nieva, MD, Oncologist and Hematologist,Billings Clinic,Billings Montana
•Harry Glorikian, Managing Partner and Founder, Scientia Advisors
•Paul Dempsey, Ph.D., Chief Science Officer, CynvenioBiosystems
•Scott Kern, M.D., Professor of Oncology and Pathology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine
•About Cambridge Healthtech Institute

TABLES

•Exhibit 4.1 Screening, detection, risk, and monitoring biomarkers
•Exhibit 4.2 Prognosis and prediction biomarkers
•Exhibit 4.3 Companion diagnostic biomarkers
•Exhibit 5.1 Estimated cancer biomarker manufacturer revenues (2012) and projections (2017), by segment (US$ in billions)
•Exhibit 5.2 Selected recent cancer detection, risk, and prognostic assay deals
•Exhibit 5.3 Selected recent companion diagnostic assay deals
•Exhibit 5.4 Survey: Area of respondents’ work
•Exhibit 5.5 Survey: Nature of respondents’ organization
•Exhibit 5.6 Survey: Respondents’ position within their organization
•Exhibit 5.7 Survey: Respondent’s biomarker focus (Multiple answers permitted; n=107)
•Exhibit 5.8 Survey: Respondents’ organization employs which of the following technologies for cancer biomarker detection of measurement (Multiple answers permitted; n=100)
•Exhibit 5.9 Survey: Statements regarding circulating tumor cells and nucleic acids (Multiple answers permitted; n=100)
•Exhibit 5.10 Survey: Participation in companion diagnostics (Multiple answers permitted; n=100)
•Exhibit 5.11 Survey: On a scale of 1 to 5, please rate the following entities as likely sources for new cancer biomarkers during the next five years (1=Highly unlikely; 5=Highly likely)
•Exhibit 5.12 Survey: On a scale of 1 to 5, please rate the following technologies as likely means for detecting or measuring cancer biomarkers during the next five years (1=Highly unlikely; 5=Highly likely)

FIGURES

•Figure 4.1 Cynvenio's LiquidBiopsy Platform

Read the full report:

Molecular Biomarkers for Cancer Detection and Management

http://www.reportbuyer.com/countries/north_america/usa/molecular_biomarkers_cancer_detection_management.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Genomics

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: query@reportbuyer.com
Tel: +44 208 816 85 48
Website: http://www.reportbuyer.com

Read the full story at http://www.prweb.com/releases/2013/11/prweb11313928.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Coordinating the circadian clock: Molecular pair controls time-keeping and fat metabolism
2. Molecular probes identify changes in fibronectin that may lead to disease
3. Small molecular bodyguards kill HPV-infected cancer cells by protecting tumor-suppressor
4. Molecular subtypes and genetic alterations may determine response to lung cancer therapy
5. Scientists discover distinct molecular subtype of prostate cancer
6. New molecular structure offers first picture of a protein family vital to human health
7. Grb2 holds powerful molecular signaling pathway in check
8. Better treatment for brain cancer revealed by new molecular insights
9. Media alert: 24th EORTC - NCI - AACR Symposium Molecular Targets and Cancer Therapeutics
10. Researchers unveil molecular details of how bacteria propagate antibiotic resistance
11. Molecular switch identified that controls key cellular process
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... PawPaws ... a new product that was developed to enhance the health of felines. The formula ... , The two main herbs in the PawPaws Cat Kidney Support Supplement ...
(Date:6/25/2016)... ... 2016 , ... Experts from the American Institutes for Research ... June 26-28, 2016, at the Hynes Convention Center in Boston. , AIR experts ... planning, healthcare costs and patient and family engagement. , AIR researchers will be ...
(Date:6/25/2016)... ... 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users can ... CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn ... X . Simply select a ProHand generator and drag it above media or text ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin ... injury. Recently, he has implemented orthobiologic procedures as a method for treating his ... of the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June ... with. The article goes on to state that individuals are now more comfortable seeking ... common operations such as calf and cheek reduction. The Los Angeles area medical group, ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... June 23, 2016 Roche (SIX: RO, ROG; ... for its Elecsys BRAHMS PCT (procalcitonin) assay as a ... septic shock. With this clearance, Roche is the first ... integrated solution for sepsis risk assessment and management. ... infection and PCT levels in blood can aid clinicians ...
(Date:6/23/2016)... MOUNTAIN VIEW, Calif. , June 23, 2016 ... 9:00 a.m. CST on Thursday, July 7, 2016 , , ... kayla.belcher@frost.com ) , , , , EXPERT PANELISTS:  ... Sciences, Nitin Naik; Senior Industry Analyst, Christi Bird; Senior Industry Analyst, ... The global pharmaceutical industry is witnessing ...
(Date:6/23/2016)... , June 23, 2016 The vast ... an outpatient dialysis facility.  Treatments are usually 3 times ... hours per visit, including travel time, equipment preparation and ... patient, but especially grueling for patients who are elderly ... a skilled nursing and rehabilitation centers for some duration ...
Breaking Medicine Technology: